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Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. We
investigated this pattern using both a human specimen and rat models. In the human specimen, a substantial fraction of
infiltrating tumor cells were located along perivascular spaces in close relationship with endothelial cells. Brain xenografts of
U87MG cells treated with bevacizumab were smaller than controls (p = 0.0055; Student t-test), however, bands of tumor cells
spread through the brain farther than controls (p < 0.001; Student t-test). Infiltrating tumor Cells exhibited tropism for vascular
structures and propensity to form tubules and niches with endothelial cells. Molecularly, bevacizumab triggered an epithelial
to mesenchymal transition with over-expression of the receptor Plexin Domain Containing 1 (PLXDC1). These results were
validated using brain xenografts of patient-derived glioma stem-like cells. Enforced expression of PLXDC1 in U87MG cells
promoted brain infiltration along perivascular spaces. Importantly, PLXDC1 inhibition prevented perivascular infiltration and
significantly increased the survival of bevacizumab-treated rats. Our study indicates that bevacizumab-induced brain
infiltration is driven by vascular endothelium and depends on PLXDC1 activation of tumor cells.
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Introduction
Glioblastoma (GBM), the most malignant primary brain
tumor in adults, is a highly vascularized cancer. Standard-of-
care treatment consists in surgery followed by chemo-radia-
tion; nevertheless, the median survival is only 14.6 months
due to tumor recurrence.1 Advances in the molecular under-
standing of gliomagenesis have led to targeted therapies with
one of the main targets being VEGF. VEGF and its receptors
are highly expressed in both endothelial cells and GBM and
VEGF mRNA up-regulation is triggered by hypoxia through
stabilization of hypoxia-inducible factor-1.2 Moreover, VEGF
is produced by GBM stem-like cells (GSCs) in the vascular
niche.3–5 The importance of angiogenesis in maintenance and
progression of GBM has prompted the development of bevaci-
zumab, a monoclonal antibody against VEGF, which currently
is the only FDA-approved targeted agent for recurrent GBM.
However, results of recent trials with bevacizumab are
openly discordant.6–8 A sustained response to bevacizumab
therapy is not the rule in GBM, whereas tumor regrowth
after initial response is frequently seen, suggesting resistance
mechanisms and secondary re-angiogenesis after transient
normalization of tumor vessels. In addition, treatment with
bevacizumab may trigger a phenotypic change in GBM that
acquires a gliomatosis-like growth pattern.9–11 Though its
actual prevalence has been questioned, the infiltrative growth
of GBM after bevacizumab treatment is described in several
studies both on clinical11–15 and on pathological basis.9,16,17
Glioblastoma is thought to escape from antiangiogenic treat-
ment using two mechanisms, a proangiogenic evasion, in
which the tumor upregulates alternative proangiogenic path-
ways, and a proinvasive shift, in which the tumor modifies
its phenotype and propagates to distant sites without reini-
tiating angiogenesis.18 On magnetic resonance imaging
(MRI), proangiogenic evasion manifests as nodular contrast-
enhancing regrowth at the initial site of disease, whereas the
proinvasive shift is recognizable by nonenhancing, fluid-
attenuated inversion recovery (FLAIR)-bright areas without
signs of revascularization (Figs. 1a and 1b). Here, we analyzed
a surgically resected GBM that recurred after treatment with
bevacizumab and that showed an infiltrative growth pattern on
MRI. Pathological data from this specimen were exploited to
set up orthotopic models of fluorescent human GBM xeno-
grafts that allowed us to dissect morphologically and molecu-
larly the infiltrative growth induced by bevacizumab.
Materials and Methods
Clinical material
A surgical specimen of temporal lobe was fixed in formalin
and paraffin-embedded. Four-μm thick paraffin sections were
dewaxed with xylene and rehydrated in ethanol. Combined immu-
nophenotyping with antibody antihuman CD31 (Monoclonal
Mouse, clone JC70A, 1:50 dilution, Dako, Milan, Italy) and fluores-
cence in situ hybridization (FISH) using LSI EGFR Probe (Vysis
EGFR/CEP7 FISH Probe Kit, Abbott, Rome, Italy) was performed
as described (Supporting Information Methods).19 Sections were
incubated overnight at 4 C in PB with 0.3% Triton X-100 and
0.1% NDS with Lectin from Lycopersicon esculentum (tomato) bio-
tin conjugate (1:500; Sigma-Aldrich, St. Louis, MO) together with
Monoclonal Mouse Anti-IDH1 (R132H; clone HMab-1, 1:50,
Sigma Aldrich, St. Louis, MO). Monoclonal Rat Anticollapsin
Response-Mediated Protein 5 (CRMP5, 1:50, Millipore, Billerica,
MA) antibody was also used to stain GBM cells.20 Slides were
counterstained with DAPI (Vectashield mounting medium with
Dapi, Vector Laboratories). Images were captured using a Laser
Scanning Confocal Microscope (IX81, Olympus Inc, Melville, NY).
Culture of tumor cells and lentiviral infection
The U87MG human GBM cell line was purchased from the
American Type Culture Collection (Manassas, VA). A patient-
derived GSC line, namely the GSC1 cell line, was also used.5 Cells
were cultured and virally transduced for green fluorescent protein
(GFP) and m-Cherry expression, and for PLXDC1 over-expres-
sion/down-regulation as described in Supporting Information
Methods.
Cell growth and migration
For proliferation assay, GFP, PLXDC1-GFP and shPLXDC1-GFP
U87MG cells were plated at density of 8 × 103/mL in 96 well
plates in triplicate. Cell proliferation and migration were evalu-
ated as described in Supporting Information Methods.
Invasion assay on endothelial cords
An in vitro co-culture system containing a feeder layer of
adipose-derived stem cells (ADSCs), which are similar to mes-
enchymal stem cells, and endothelial colony forming cells
(ECFCs), a subtype of umbilical cord blood-derived endothe-
lial cells which can form vascular networks, was used to ana-
lyze motility and invasion of U87MG cells (Supporting
Information Methods).21
What’s new?
Bevacizumab, a VEGF-targeting monoclonal antibody, has been observed to trigger an infiltrative growth pattern in
glioblastoma as an escape mechanism. The mechanisms underlying this gliomatosis-like growth pattern, however, remain
unclear. Here, the authors found that the infiltrative growth pattern occurs mostly along perivascular spaces and relies on the
over-expression of PLXDC1 by tumor cells and on the restoration of the endothelial component of blood brain barrier.
Altogether, the data show that the brain infiltration induced by bevacizumab is mainly driven by the vascular endothelium.
Importantly, inhibition of PLXDC1 prevents bevacizumab-induced infiltrative growth, resulting in significant increase of survival.
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Intracranial xenografts of fluorescent U87MG or GSC1 cells
Experiments involving animals were approved by the Ethical
Committee of the Università Cattolica del Sacro Cuore
(UCSC), Rome (Pr. No. CESA/P/51/2012). Immunosup-
pressed athymic rats (male, 250–280 g; Charles River, Milan,
Italy) were anesthetized with intraperitoneal injection of diaz-
epam (2 mg/100 g) followed by intramuscular injection of
ketamine (4 mg/100 g). Animal skulls were immobilized in a
stereotactic head frame and a burr hole was made 3 mm right
of the midline and 2 mm anterior to the bregma. The tip of a
10 μL-Hamilton microsyringe was placed at a depth of 5 mm
from the dura and 2 × 104 of either m-Cherry+ or GFP+
U87MG or GFP+ GSC1 cells were slowly injected. After graft-
ing, the animals were kept under pathogen-free conditions
and observed daily for neurological signs. Treatment with bev-
acizumab (10 mg/kg i.p. twice weekly) was initiated 4 days
and 12 weeks after implantation in the rats grafted with
U87MG and GSC1 cells, respectively. Control animals were
treated with isotype IgG. After survivals ranging from 14 days
to 16 weeks, the rats were deeply anesthetized and transcar-
dially perfused with 0.1 M PBS (pH 7.4) then treated with 4%
paraformaldehyde in 0.1 M PBS. The brain was removed and
stored in 30% sucrose buffer overnight at 4  C.
Fluorescence microscopy and immunofluorescence of brain
tumor xenografts
The brains were serially cryotomed at 40 μm on the coronal
plane. Sections were collected in distilled water and mounted
on slides with Vectashield mounting medium (Bio-Optica,
Milan, Italy). Images were acquired with a laser scanning con-
focal microscope (LSM 500 META, Zeiss, Milan, Italy). The
cranio-caudal extension of the brain tumor was assessed on
serial coronal sections. The tumor volume was determined as
described.21 For immunofluorescence, sections were blocked
in PB with 10% BSA, 0.3% Triton X-100 for 45 min and incu-
bated overnight at 4 C with primary antibodies in PB with
0.3% Triton X-100 and 0.1% normal donkey serum (NDS).
Monoclonal antibodies used were as follows, mouse antirat
blood–brain barrier (Clone SMI-71) (1:500; Biolegend, San
Diego, CA), mouse antihuman smooth muscle actin (Clone
1A4) (1:1000, DAKO Agilent, Santa Clara, CA). Polyclonal
antibodies used were as follows, goat anti-CD34 (C-18) (1:50;
Santa Cruz biotechnology, Dallas, TX), rat antimouse CD31
(1:100) (BD Bioscience, Franklin Lakes, NJ), rabbit anti-GFAP
(1:1000; Dako Italia, Milan, Italy). For detecting brain micro-
vessels, sections were incubated overnight at 4 C in PB with
0.3% Triton X-100 and 0.1% NDS with Lectin from Lycopersi-
con esculentum (tomato) biotin conjugate (1:500; Sigma-
Aldrich, St. Louis, MO) together with primary antibodies.
Slices were rinsed and incubated in PB containing 0.3% Triton
X-100 with secondary antibodies for 2 h at RT. Secondary
antibodies used were as follows: Alexa Fluor 647 or 555 or
488 donkey antimouse, Alexa Fluor 488 or 555 or 647, donkey
antirabbit secondary antibodies (1:500; Thermo Fisher Scientific,
Waltham, MA), Alexa Fluor 488 or 555 donkey antigoat anti-
bodies (1:400; Thermo Fisher Scientific, Waltham, MA), Cy3
donkey antirat (1:200, EMD Millipore, Billerica, MA). For lectin
immunostaining, sections were incubated for 2 h at RT in PB
containing 0.3% Triton X-100 with streptavidin protein, DyLight
405 conjugate or streptavidin Alexa Fluor® 647 conjugate (1:200;
Thermo Fisher Scientific, Waltham, MA). Before mounting, slices
were incubated with DAPI (1:4000; Sigma-Aldrich) for 10 min.
Immunofluorescence was observed with a laser confocal micro-
scope (SP5; Leica) and images were acquired. Image analysis was
performed with Leica Application Suite X software.
Gene expression profiling of U87MG cells after in vivo
treatment with bevacizumab
Twenty-eight days after grafting, the brains treated either with
bevacizumab (10 mg/kg i.p. twice weekly) or with isotype IgG
were removed and mechanically dissociated to obtain single
cell suspensions. The fluorescent m-Cherry U87MG cells were
isolated by using FACSAria cell sorter (BD Biosciences, Milan,
Italy). Total RNA was extracted from cells using TRIzol
reagent (Life Technologies Corporation), labeled and hybrid-
ized to the Affymetrix GeneChip1.0ST array (Affymetrix,
Santa Clara, CA) according the manufacturer’s instructions.
Gene expression analysis was performed on two samples for
each group (bevacizumab vs. isotype IgG treated rats) from
two independent experiments. Data preprocessing prior to the
formal statistical analysis involved standard processes of nor-
malization [robust Multi-array Average (RMA) method]. All
data analysis was performed with R (http://www.R-project.
org) using Bioconductor.22 Differentially regulated genes were
determined with LIMMA23 applying default parameters and a
FDR-corrected p value cutoff <0.05. Generation of the unified
dataset involved through two consecutive steps. Gene set enrich-
ment analysis was based on MSigDB using the GSEA online
tool24 hosted by the Broad Institute (http://www.broadinstitute.
org/gsea/index.jsp).
Real-time quantitative PCR
Total RNA was isolated from shCNTR-GFP and shPLXDC1-GFP
U87MG cells, and from GSC1 cells using TRIzol reagent (Life
Technologies Corporation). PrimePCR™ precasted 96-well EMT
pathway plate was purchased from Bio-Rad (Bio-Rad Laborato-
ries, Inc. Hercules, CA). One microgram of RNA was reverse-
transcribed into cDNA using iScript cDNA Synthesis Kit from
Bio-Rad, according to the manufacturer’s instructions. Real-time
qPCR reactions were carried out as described by Bio-Rad in the
PrimePCR™ instruction manual, including experimental control
assays for reverse transcription (PrimePCR™ Reverse Transcrip-
tion Control SYBR1 Green Assay), genomic DNA (PrimePCR™
DNA Contamination Control SYBR1 Green Assay), RNA quality
(PrimePCR™ RNA Quality SYBR1 Green Assay) and PCR per-
formance (PrimePCR™ Positive Control SYBR1 Green Assay).
RT-PCR was performed on a CFX96 Touch Real-time PCR
Detection System (Bio-Rad) using SsoAdvanced™ Universal
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SYBR1 Green Supermix. The data were analyzed using the
Bio-Rad CFX manager 3.1 software system. The samples
were normalized against 3 reference genes; actin beta (ATCB),
hypoxanthine phosphoribosyltransferase 1 (HPRT1) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical analysis
Statistical significance was assessed by a two-tailed Student t-test
with equal variance compared to the data obtained for saline
controls. Statistical significance was assigned to p values <0.05.
Results
Bevacizumab-induced infiltrative growth of human GBM
exploits the perivascular space
A surgically resected temporal lobe was assessed by histology
and fluorescence microscopy. This 31-year-old man had
undergone a first craniotomy in January 2009 at another insti-
tution for partial removal of a right parietal GBM (WHO IV).
After surgery, he received radiotherapy and temozolomide
according to the Stupp protocol.1 A second craniotomy was
performed in October 2009 at our center for local tumor
recurrence (Fig. 1b, top left). Histology confirmed the diagno-
sis of GBM. On pathological analyses, Ki-67 labeling index
was 20%, O6-methylguanine-DNA methyltransferase promoter
was unmethylated, EGF receptor (EGFR) was amplified, EGFR
variant III was expressed, and isocitrate dehydrogenase (IDH)-
1 was mutated. After the second craniotomy, due to residual
enhancing tissue adjacent to the lateral ventricle, antiangiogenic
treatment with bevacizumab was initiated (Avastin®, 10 mg/kg
i.v. every 2 weeks in 6-week cycles) (Fig. 1b, top right). By the
third cycle of bevacizumab, follow-up MRI showed reduction
of the paraventricular area of contrast enhancement, however,
the right temporal lobe appeared swollen due to diffusely infil-
trating tissue that did not enhance after administration of con-
trast medium (Fig. 1b, bottom left). In January 2011, due to
headache and poorly controlled seizures, a third craniotomy
was performed with resection of the right temporal lobe in an
en bloc fashion. Histological examination showed an increased
cell density due to enlarged cells with atypical nuclei, which
were mainly located along the perivascular spaces (Fig. 1b, bot-
tom right). Fluorescence microscopy combining immunohisto-
chemistry for CD31 and FISH for EGFR showed that a
substantial fraction of tumor cells with amplified EGFR signals
lied close to CD31-expressing endothelial cells (Fig. 1c). In
tumor regions as far as 12 cm from the primary neoplasm, we
calculated a 7:5 ratio between the tumor cells that were spatially
associated with the vascular endothelium and those that were
not. These results were confirmed by fluorescence microscopy
combining anti-IDH1 or anti-CRMP5 immunostaining, which
selectively labeled the tumor cells,20 either with lectin staining
of the blood vessels or with anti-CD31 immunofluorescence,
that selectively stains the endothelial cells (Fig. 1d). Using these
techniques, we confirmed the perivascular tumor growth in the
nonenhancing FLAIR-hyperintense temporal lobe. However, in
this region we did not recognize morphological patterns of vas-
cular mimicry and vessel cooption, which were seen in the
specimen obtained at surgery for tumor recurrence in the parie-
tal region, i.e., at the site of primary surgery (Supporting Infor-
mation Fig. S1). Taken together, these studies demonstrate that
the perivascular spaces are preferential routes for tumor spread-
ing in bevacizumab-induced infiltrative shift of GBM.
Effect of bevacizumab on the invasive behavior of U87MG
cells in vitro
Based on the histologic data of our patient, we hypothesized
that the infiltrative shift occurring after bevacizumab therapy
for GBM may involve changes in the perivascular environ-
ment that would become more permissive to the invading
cells. Then, we aimed to reproduce in vitro conditions that
mimic the in vivo interactions between GBM cells and peri-
vascular environment using an invasion assay on endothelial
cords.21 The human U87MG cell line was chosen because its
growth depends on angiogenesis and VEGF signaling.25,26
Cords of human ECFCs were established using an in vitro col-
ony formation assay, and GFP expressing U87MG cells, pre-
treated with 2.5 mg/mL of either IgG or bevacizumab for
72 h, were seeded in the top chamber of a cell invasion assay.
Both the top and bottom chambers were also treated with either
IgG or bevacizumab (final concentration 2.5 mg/mL). We found
that the presence of U87MG cells resulted in marked increases
in connected tube area of established cords, both in wells that
received IgG-pretreated U87MG cells and in those with
bevacizumab-pretreated U87MG cells (Supporting Information
Fig. S2A). Interestingly, the U87MG cells invaded through the
matrix of the chamber. At 48 h post seeding, bevacizumab-
pretreated cells exhibited a slightly higher invasive growth com-
pared to IgG-pretreated cells, when the co-culture was used as
the “chemoattractant” (Supporting Information Fig. S2B).
Bevacizumab-pretreated U87MG cells indicated a tendency to
line up adjacently to the endothelial cords, though there was not
a significant overlap of U87MG cells with the cords, as assessed
by automated image analysis (Supporting Information Fig. S2C).
These findings suggest that in an in vitro model system, bevaci-
zumab increased the tropism of U87MG cells toward the vascu-
lar endothelium, however, it did not significantly enhance
migration along the endothelial cord surface.
Effect of bevacizumab on the invasive growth of U87MG
brain xenografts
In the attempt to reproduce the complex environment in which
bevacizumab induces the infiltrative growth of GBM, we grafted
fluorescent U87MG cells (expressing either m-Cherry or GFP)
onto the striatum of athymic rats and assessed the effects of
bevacizumab (10 mg/kg i.p. twice weekly for 3 weeks) on the
growth pattern of tumor xenografts. Three weeks after brain
grafting, isotype IgG treated control rats showed compact
tumor masses with sharply defined edges (Figs. 2a and 2b). At
this time, the rats developed clinical signs, including >20%
1334 Bevacizumab-induced infiltrative shift
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weight loss, spastic gait, and lethargy. Analysis of the tumor
margins did not reveal regions of brain infiltration. Occasion-
ally, the tumor border showed irregular profiles (Fig. 2b, right
panel), which occurred in proximity of the rhinal fissure and
likely resulted from the passive resistance offered by arachnoid
or vascular structures. Only rare were tumor cells scattered in
the brain up to a maximal distance of 660 μm from the tumor
margin (Fig. 2c). Lectin staining for endothelial structures
showed that capillaries and venules crossing the brain-tumor
interface were surrounded for short distances by a few tumor
cells (Fig. 2d). Bevacizumab-treated tumors were significantly
smaller than controls (Fig. 2e). Three weeks after grafting, the
tumor volume was 116.5  23.1 mm3 (mean  sem, n = 3)
and 17.7  2.5 mm3 (mean  sem, n = 3) in control and
bevacizumab-treated tumors, respectively (p < 0.02; Student-t
test). However, the latter tumors showed deposits on the walls
of the ventricles (Fig. 2e, arrows). The margins of bevacizumab-
treated tumors were quite irregular due to bands or islands of
tumor cells that spread onto the surrounding brain (Fig. 2f ).
Analysis of brain regions surrounding the tumor revealed that
the tumor cells arranged themselves to form multiple shaped
structures including, satellites, multilayered columns, chain-like
files, and isolated cells. Satellites and multilayered columns are
likely to represent different aspects of vessel cooption, a process
whereby the tumor cells organize themselves into cuffs around
microvessels. The chains of cells in single file likely reflect an
acquired attitude of the tumor cells to form tubular structures,
a phenomenon referred to as tubulogenesis. Isolated cells dem-
onstrated enhanced potential of the tumor for cell motility and
brain invasion. Three weeks after grafting, the distance traveled
by the tumor cells through the brain was significantly longer in
bevacizumab-treated rats than in control ones (p < 0.001;
Student-t test) (Figs. 2c and 2g). In bevacizumab treated xeno-
grafts, tumor satellites and multilayered columns were always
associated with endothelial structures, thus confirming that they
resulted from vessel cooption. The chain-like arrangement of
tumor cells featured mosaic tubule formation reminiscent of
vascular mimicry (Fig. 2h). Isolated tumor cells exhibited elon-
gated morphology and a strict tropism for the endothelial ele-
ments (Fig. 2h and Supporting Information Fig. S3). Bevacizumab
significantly reduced microvessel density in the xenografts (Fig. 2i,
left panel). By 28 days after grafting, in bevacizumab-treated xeno-
grafts 85.7% of tumor cells that lied farther than 500 μm from the
tumor margin had established cell-to-cell interactions with endo-
thelial elements (Fig. 2i, right panel). Therefore, the orthotopic
U87MG grafting model did reproduce the bevacizumab-induced
infiltrative shift of human GBM confirming that this phenomenon
occurs mostly along the perivascular spaces.
Molecular changes induced by bevacizumab on U87MG cells
in vivo
Grafting of fluorescent GBM cells provides the opportunity to
retrieve selectively the tumor cells from the brain by FACS and
Figure 1. Radiological and morphological assessment of bevacizumab
treatment on recurrent GBM. (a) Magnetic resonance (MR) imaging
(T1-weighted Gd enhanced) showing an illustrative case of response to
bevacizumab and late tumor regrowth (arrows, recurrent tumor; in
brackets, follow-up in months). (b) Axial Gd-enhanced T1-weighted MR
imaging of reported case (upper panel). Twelve months after primary
surgery, an area of contrast enhancement developed adjacent to the
lateral ventricle (arrow). The right temporal lobe showed normal
FLAIR signal. After bevacizumab therapy (lower panel), the contrast
enhanced area in the right para-ventricular region disappeared (left;
arrow), however, the right temporal lobe swelled due to hyper-intense
diffusely infiltrating lesion on FLAIR sequence (in brackets, follow-up in
months). Histological picture (lower panel, right) of the resected temporal
lobe (brain region framed in FLAIR image). The temporal lobe parenchyma
appears infiltrated by rare cells with atypical nuclei that are in close
relationship with the capillaries (arrows). H&E. Scale bars, 150 μm (left)
and 70 μm (right). (c) Combined anti-CD31 immunohistochemistry and
FISH for the EGFR probe showing the tumor cell nuclei with amplified EGFR
signals either isolated (arrowheads) or in close relationship with CD31+
endothelial cells (arrows). Scale bars, 10 μm. (d) Immunofluorescence
with anti-IDH1 antibody for selective staining of tumor cells combined with
lectin staining of vascular structures. Validation of IDH1 immunoreaction
on primary cell cultures of patient-derived IDH1 mutated GBM (left panels).
The infiltrating IDH1-positive tumor cells (red) lie in close proximity with
vessels along the perivascular spaces (arrows). Scale bars, 150 μm (left)
and 40 μm (centre and right panels).
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to analyze the molecular changes elicited by bevacizumab
in vivo. Analyzing the molecular changes of GBM under in vivo
conditions is of paramount importance, since transcriptional reg-
ulators that enable cells to proliferate in the tumor microenviron-
ment in vivo are nonoverlapping with those required in vitro.27
To this aim, athymic rats grafted with fluorescent U87MG cells
were treated with bevacizumab (10 mg/kg i.p. twice weekly for
3 weeks). Three weeks later, their brains were removed,
fluorescent cells were sorted, and their gene expression profile
was compared to that of tumor cells sorted from isotype IgG
treated control xenografts. Results of gene expression analysis
showed that the highest modulated genes were those involved in
epithelial to mesenchymal transition (EMT) and hypoxia
(Fig. 3a). Among the highest modulated genes, we found the
receptor Plexin Domain Containing 1, PLXDC1 (or Tumor
Endothelial Marker-7, TEM-7), a trans-membrane protein
FIGURE 2. Legend on next page
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known to be expressed by GBM associated endothelial cells.28,29
TGF-β1, extracellular matrix remodeling genes, and several
others which define the mesenchymal signature were found sig-
nificantly up-regulated after in vivo treatment with bevacizumab
as compared to isotype IgG treated U87MG cells (Supporting
Information Table S1).
To assess the role of PLXDC1 in bevacizumab-induced infil-
trative shift, we over-expressed and down-regulated this receptor
in U87MG cells (PLXDC1-GFP U87MG and shPLXDC1-GFP
U87MG, respectively). Over-expression and down-regulation of
PLXDC1 was verified by RT-PCR and flow cytometry (Fig. 3b).
In vitro, PLXDC1-GFP U87MG cells exhibited increased prolifer-
ation and migration whereas shPLXDC1-GFP U87MG cells
showed decreased proliferation and migration as compared to
control GFP U87MG cells (Fig. 3b). We then grafted
PLXDC1-GFP U87MG and GFP U87MG cells onto the striatum
of athymic rats. As expected, control GFP U87MG cells devel-
oped compact tumors with sharp margins (Fig. 3c, right). Xeno-
grafts arising from PLXDC1-GFP U87MG cells exhibited profiles
suggesting vessel cooption (Fig. 3c, left). Then, over-expression of
PLXDC1 in U87MG cells elicited vessel cooption, although it was
not sufficient per se to trigger all the repertoire of brain invasion
induced by bevacizumab.
Effect of bevacizumab on the growth of GSC brain
xenografts
To validate the effect of bevacizumab on perivascular spread-
ing of GBM cells and the role of PLXDC1 in this process, we
developed brain xenografts of patient-derived GSCs, which
are known to closely mimic the human tumor. To this pur-
pose, 12 weeks after grafting GFP-expressing GSC1 cells onto
the striatum of athymic rats, we administered bevacizumab
(10 mg/kg i.p. twice weekly) for 3 weeks. One week after the
end of treatment, we compared their brains with those of iso-
type IgG treated control rats. Differently from the U87MG
cells, GSC1 cells developed highly infiltrating tumors (Supporting
Information Fig. S4A). Tumor cells invaded the homolateral stri-
atum and piriform cortex and extended contralateral through the
corpus callosum, anterior commissure, septal nuclei, and optic
chiasm. Brain invasion occurred mostly along these axonal paths,
however, a remarkable fraction of tumor cells traveled along
the perivascular spaces (Supporting Information Fig. S4B-C). In
spite of reduction of tumor cell density in the grafted striatum
and subcortical white matter, bevacizumab did not inhibit the
growth of GSC1 tumors to the same extent as in U87MG xeno-
grafts (Supporting Information Fig. S4D). However, bevacizu-
mab strongly increased perivascular spreading of GSC1 cells
(Supporting Information Fig. S4E-F). In some areas, GSC1 cells
completely encased the blood vessels in a parasitic manner. We
then interrogated whether PLXDC1, that was heavily involved
in the response of U87MG cells to bevacizumab, may also play
a role in GSCs. To this aim, we performed Real-Time PCR
analysis of GSC1 cells retrieved from the brain of rats treated
with bevacizumab or with isotype IgG. Results showed that, as
compared to IgG treated controls, PLXDC1 mRNA increased
by 2.1 times in GSC1 treated with bevacizumab (Supporting
Information Fig. S4G). These data support the concept that
bevacizumab enhances perivascular growth of GBM cells and
that PLXDC1 does have a role in this process.
PLXDC1 as target against the bevacizumab-induced
infiltrative shift of U87MG cells
To establish the actual role of PLXDC1 in bevacizumab-
induced infiltrative shift and to explore its potential value as
therapeutic target, brain xenografts were established using
shPLXDC1-GFP U87MG cells and the rats were treated with
bevacizumab (10 mg/kg i.p. twice weekly for 3 weeks). Controls
included either rats grafted with scrambled shRNA (shCNTR)-
GFP U87MG cells and treated with isotype IgG, rats grafted
with scrambled shCNTR-GFP U87MG cells and treated with
bevacizumab, or rats grafted with shPLXDC1-GFP U87MG
cells and treated with isotype IgG. Three weeks after grafting,
tumor xenografts arising from shPLXDC1-GFP U87MG cells
that received bevacizumab were significantly smaller than all
control groups (p < 0.002; Student t-test) and did not show
perivascular spreading (Figs. 4a–4c). Importantly, the rats
Figure 2. Tumor xenografts generated by m-Cherry expressing U87MG cells implanted in the brain of athymic rats and treated with
bevacizumab or isotype IgG. (a) By 28 days after grafting, in control IgG-treated rats the tumor appears as a compact mass with sharply
defined edges. Scale bar, 1 mm. (b) Analysis of the tumor margins does not reveal regions of brain infiltration. Occasionally, the tumor
margin may show an irregular profile. This occurs as the tumor approaches the rhinal fissure and likely results from the passive
resistance offered by arachnoidal structures. Scale bar, 70 μm. (c) Higher magnification view showing single tumor cells in the brain up
650 μm from the tumor margin (T, tumor). Bar graph showing the distance traveled into the brain by control and bevacizumab-treated
tumor cells (**, p < 0.01). (d) Staining of vascular structures with lectin (green) demonstrates a few tumor cells that surrounded
capillaries and venules at the brain-tumor interface. Scale bars, 100 μm. (e) Bevacizumab-treated tumor xenografts are smaller than
controls, however, metastases spread along the CSF pathways (arrows). Scale bar, 1 mm. (f ) Tumor cells arranged in satellites, finger-
like extensions, and chain-like files. Scale bar, 70 μm. (g) Isolated tumor cells are scattered in the peritumor tissue for considerable
distances. H, Both at the margin and far from the tumor bulk, the m-Cherry U87MG cells show a strict tropism for the vascular
endothelial cells (green, lectin). Scale bars, 50 μm. (i) Micro-vessel density is significantly lower in bevacizumab-treated xenografts (bottom left
panel, arrows) as compared to control IgG-treated ones (upper left panel, arrows; green, CD31 immunostaining). In bevacizumab-treated tumors,
the U87MG cells that established cell-to-cell interactions with endothelial elements had spread through the brain for much longer distances
than those U87MG cells that were not spatially associated with the lectin-positive cells (right panel).
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grafted with shPLXDC1-GFP U87MG cells and treated with
bevacizumab survived significantly longer than other groups,
including rats grafted with shPLXDC1-GFP U87MG and trea-
ted with isotype IgG (p = 0.002, log rank test; Fig. 4c). These
results demonstrate that PLXDC1 downregulation is not suffi-
cient per se to inhibit the growth of U87MG brain xenografts
but can exert an inhibitory effect in conditions of reduced avail-
ability of VEGF, like bevacizumab therapy.
Figure 3. Molecular changes elicited by bevacizumab in vivo on U87MG cells and effects of PLXDC1 over-expression. (a) GSEA of highly modulated
genes as assessed by gene expression array on U87MG cells retrieved from the brain of bevacizumab treated rats compared to IgG treated controls.
(b) FACS analysis (upper panel), RT-PCR analysis and proliferation assay (middle panel), and migration assay (lower panel) of control GFP, PLXDC1-GFP
and shPLXDC1-GFP U87MG cells. (c) In vivo effects of PLXDC1 over-expression. Brain xenografts of GFP U87MG and PLXDC1-GFP U87MG cells showing
perivascular growth (arrows; U87MG cells, green; lectin, red). Xenografts of control U87MG cells do not infiltrate the brain.
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PLXDC1 alters the expression pattern of epithelial and
mesenchymal markers in U87MG cells
To investigate more in details the molecular mechanisms through
which PLXDC1 modulates the perivascular spreading of U87MG,
the expression of several mesenchymal and epithelial marker
genes was carried out by RT-PCR analysis on shPLXDC1-GFP
and shCNTR-GFP U87MG cells. The mRNA levels of epithelial
transcripts, such as E-cadherin (CDH1) and Keratin 14 (KRT14)
were significantly increased, whereas mesenchymal marker genes,
such as vimentin (VIM), TGFB1, TGFB 2 and TGFB 3, occludin
(OCLN), and ZEB1 and ZEB2 among others, were significantly
reduced in shPLXDC1-GFP U87MG cells compared to shCNTR-
GFP U87MG cells (Supporting Information Fig. S5). These results
suggest that PLXDC1 silencing inhibits the EMT program
induced by bevacizumab.
Relationships of U87MG tumor cells, astrocyte endfeet, and
blood brain barrier (BBB)
Taken together, our results indicate that in response to bevacizu-
mab the U87MG cells, which possess a poor intrinsic ability to
invade the brain, become able to migrate using the perivascular
spaces as route for spreading. This invasive behavior depended
on the up-regulation of PLXDC1 triggered by bevacizumab.
Then, we focused on the cell components of perivascular envi-
ronment. In the brain, the vascular endothelium is covered by
astrocytic endfeet that may pose an obstacle to glioma cells
invading along blood vessels.30 Theoretically, perivascular glioma
cells may either travel outside the astrocytic endfeet, thereby pre-
serving the BBB, or disrupt astrocyte covering through the elimi-
nation of endfeet and BBB. In order to dissect morphologically
the relationships between glioma cells, astrocytes, and brain
endothelium, we used fluorescently labeled U87MG cells and
type-specific markers. Astrocytes and BBB were assessed by anti-
GFAP and anti-SMI71 immunohistochemistry, respectively
(Fig. 5, Normal). The latter marker stains selectively the endothe-
lial component of the rat BBB.31 In control isotype IgG treated
U87MG brain xenografts, SMI71 immunostaining was nearly
absent in vessels lying within the tumor and in peritumor
regions up to about 500 μm from the tumor margin (Fig. 5,
IgG). In this region, perivascular spreading of tumor cells was
quite infrequent and, where present, occurred along vessels that
lacked or showed poor SMI71 staining. Conversely, bevacizumab-
treated xenografts displayed U87MG cells that had traveled along
vessels with positive SMI71 reaction (Fig. 5, BEV). As expected,
bevacizumab partly restored the BBB in the peritumor regions.
However, the normal interaction between the astrocytic endfeet
and vasculature was disrupted by the elimination of the
endfeet altogether, whereby the U87MG cells came in direct
contact with endothelial cells that had partly restored SMI71
expression (Fig. 5, BEV). In brain xenografts of U87MG cells
over-expressing PLXDC1 treated with isotype IgG, perivascular
spreading occurred at short distances from the tumor bulk
mostly as vessel cooption around vessels that lacked SMI71
(not shown). Notably, xenografts of shPLXDC1 U87MG cells
treated with bevacizumab showed a dramatic reduction in peri-
vascular spreading in spite of restored SMI71 staining (Fig. 5,
shPLXDC1 BEV). Bevacizumab enhanced perivascular spread-
ing around pericyte coverings, however, pericytes did not pro-
liferate substantially in response to bevacizumab (not shown).
In order to invade the brain along perivascular spaces, the
U87MG cells required PLXDC1 upregulation and restoration of
the endothelial component of BBB. Importantly, inhibition of
PLXDC1 prevented the bevacizumab-induced infiltrative shift
of U87MG cells.
Discussion
Clinical and preclinical background of bevacizumab-induced
infiltrative shift in GBM
Since the first reports on the use of bevacizumab in GBM, it became
apparent that antiangiogenic therapy induces a modification of the
clinical and radiological behavior of the tumor that assumes an infil-
trating, nonenhancing gliomatosis-like growth pattern.9,13,15 The
tendency of recurrent GBM to behave more invasively after antian-
giogenic treatment and the correlation between tumor invasiveness
and hypoxia have been described in several studies.16,17 However,
some clinical studies have questioned the tendency of GBM to
become more invasive after bevacizumab treatment.12 In the ran-
domized AvaGlio trial comparing standard therapy with or without
bevacizumab, Wick et al. did not observe difference in growth pat-
terns by MRI of newly diagnosed supratentorial GBM, including
both contrast-enhancing and nonenhancing lesions.32 However, in a
more recent paper from the same group focusing on the patterns of
GBM progression in the AvaGlio trial, a T2 diffuse infiltrative pat-
tern was noticed in 12.4% of patients treated with bevacizumab and
in 7.1% of patients treated with placebo,33 suggesting that treatment
with bevacizumab may indeed cause an increased number of dif-
fusely infiltrating progressions.
On pathological examination, recurrent malignant glioma treated
with bevacizumab show diffuse neuropil infiltration with up-
regulation of invasion markers.9 It is worth noting, however, that
these observations were from small stereotactic biopsies, assessed by
conventional histology without any selective labeling of tumor cells.
Conversely, we used the amplified EGFR signal, IDH1 mutation,
and CRMP5 expression to trace selectively the infiltrating tumor cells
through the temporal lobe of our patient and we were able to dem-
onstrate that the perivascular spaces were preferential routes for the
brain invasion after bevacizumab treatment. We did not recognize
patterns of vascular mimicry as well as of vessel cooption. It should
be noted, however, that the patient sample consisted of a temporal
region with nonenhancing T2 diffuse infiltrative MRI signal lying as
far as 12 cm from the site of primitive GBM. Vessel cooption and
vascular mimicry occurred closer to the primary neoplasm, where
tumor angiogenesis is much more prominent.
Robust preclinical data support the concept of increased inva-
siveness of GBM after antiangiogenic treatment and its relationship
with vascular structures.9–11,13,14,34–36 In orthotopic murine models
of GBM treated with antiangiogenic drugs, the tumor cells invade
perivascular spaces and form satellites separated from the primary
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tumor.34,36 To investigate the effects of bevacizumab in vivo, the
U87MG brain xenograft model has widely been used because it
simulates the human condition showing a significant decrease in
contrast enhancement on MRI.37,38 Reportedly, bevacizumab
inhibits tumor growth and prolongs survival of U87 brain xeno-
grafts.39,40 In this model, the typical nodular growth pattern shifted
toward an infiltrative one after bevacizumab therapy (Supporting
Information Table S2). Satellite tumors and finger-like extensions
in the brain of bevacizumab-treated animals result from the
decreased supply of oxygen and nutrients that may act as a stimu-
lus for tumor cell migration through up-regulation of invasion-
related proteins.14 The hypothesized mechanism for explaining
the increased invasive behavior of the tumor after antiangiogenetic
therapy is cooption of existing brain vessels by the tumor to
escape the blockade of VEGF-driven angiogenesis. It has been
claimed that tumor hypoxia, which is induced by antiangio-
genic therapy, activates proinvasive survival pathways.10,11,14 In
particular, the Src family of kinases (SFKs) may play a key role
at the interface between intra and extracellular signals either
regulating cell–cell adhesion, cell-ECM adhesion, and ECM
invasion41 or by catenin phosphorylation.13
Hypotheses for the infiltrative shift after bevacizumab
therapy
Previous hypotheses for the infiltrative shift postulate that antian-
giogenic treatments decrease oxygen and nutrient supply to
Figure 4. Inhibition of PLXDC1 expression in U87MG cells prevents bevacizumab-induced infiltrative growth of brain xenografts. (a) In rats
grafted with shCNTR-GFP U87MG cells, bevacizumab treatment elicited an infiltrative growth in the perivascular spaces, as demonstrated by
tumor satellites associated with endothelial structures (arrows). Rats grafted with shPLXDC1-GFP U87MG cells and treated with bevacizumab
developed small nodular tumors with defined edges. Perivascular spreading does not occur around vessels lying close to the tumor margin
(arrows). Scale bars, 100 μm. (b) Bevacizumab treatment significantly reduced tumor volume both in shPLXDC1-GFP and in shCNTR-GFP
U87MG brain xenografts (left panel). The mere PLXDC1 inhibition does not affect significantly the volume of U87MG brain xenografts. (c) Rat
survival is significantly increased in rats grafted with shPLXDC1-GFP U87MG cells that received bevacizumab (right panel).
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tumor cells that in turn activate hypoxia-triggered up-regulation
of invasion-related proteins. The perivascular migration was
explained as a prosurvival response of the tumor cells to hypoxia.
At morphological level, the infiltrative shift is characterized by
vessel cooption, a phenomenon whereby the tumor cells migrate
along the perivascular spaces to form multilayered sleeves. Vessel
Figure 5. Assessment of relationships among U87MG tumor cells, astrocytes, and endothelial component of BBB (SMI71). In the brain of
normal rats (Normal), the endothelial cells express SMI71 and are covered by the vascular endfeets of astrocytes. In control brain xenografts
(CNTR IgG), which harbor GFP shCNTR-GFP U87MG cells and received IgG, only a few tumor cells cross the brain-tumor interface along the
perivascular spaces with disruption of the astrocytic covering (arrow). Treating xenografts of shCNTR-GFP U87MG cells with bevacizumab
(BEV) resulted in perivascular spreading. Cufs of tumor cells grew around brain vessels with restored SMI71 expression (arrow). The
astrocytic endfeets are completely displaced by the tumor cells. Inhibition of PLXDC1 in GFP U87MG cells prevented the perivascular
spreading induced by bevacizumab (shPLXDC1 BEV).
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cooption generates histological pictures such as satellites and
finger-like extensions depending on the cutting plane. However,
it is important to note that previous in vivo studies did not label
selectively the tumor cells, thus missing important aspects of the
tumor changes induced by bevacizumab. In the present study, we
used orthotopic xenografts of fluorescently labeled U87MG cells
and selectively stained the brain vessels for endothelial cell
markers, a technique that allows a much deeper dissection of the
tumor/endothelial cell interactions. In addition to vessel cooption,
we were able to identify other behaviors of U87MG cells after
in vivo treatment with bevacizumab that included, endothelium
oriented migration, mosaic tubule formation, and niching with
endothelial cells. Mechanistically, such a repertoire of vascular-
like behaviors by tumor cells are difficult to specifically define as
a pro survival response to hypoxia.
The interactions between tumor and endothelial cells elicited
by bevacizumab resemble those described by Tsai et al. during
migration of oligodendrocyte precursors cells (OPCs) along blood
Figure 6. Schematic drawing of bevacizumab-induced infiltrative growth of GBM. Perivascular spreading of tumor cells is driven by the
endothelium with restored BBB and requires activation of PLXDC1 (upper panel). PLXDC1 silencing inhibits the vascular-like infiltrative
behavior of GBM cells despite BBB restoration (lower panel).
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vessels in the developing mammalian brain.42 Glioblastoma cells
share with OPCs marker expression and propensity to migrate
over long distances. In addition, both GBM cells and OPCs
require the vascular endothelium as a physical substrate for
migration. Recently, Griveau et al. assigned a glial signature to
brain xenografts of multi-passaged subcutaneous U87 tumors
treated with bevacizumab because of increased levels of Olig2
and Nkx2.2, two transcription factors that are critical for oligo-
dendrocyte differentiation.43 On the other hand, Piao et al.
described proneural to mesenchymal transition of U87 cells
after treatment with bevacizumab that paralleled the increase in
invasive characteristics on histological examination.44 In con-
trast with studies based on xenograft models, Urup et al.
reported that in patients’ samples TGF-β1 and other genes
defining the mesenchymal signature were inactivated at the
time of progression.45 They speculate that reduced hypoxia, as
a consequence of bevacizumab-induced vascular normalization,
may lead to TGF-β1 inhibition and thus reverse mesenchymal
transition. However, clinical studies that analyzed GBM after
treatment with bevacizumab describe a sarcomatous, spindle
cell morphology with increased hypoxia markers.46 In addition,
after bevacizumab 33.3% GBMs transitioned from proneural or
proliferative to mesenchymal, whereas 25% GBMs transitioned
from mesenchymal to proneural.47 More recently, brain inva-
sion in U87 xenografts treated with bevacizumab was related
with fibroblast growth factor 13 (FGF13).35 Interestingly,
though the bevacizumab-induced tumor invasion was remark-
ably decreased in vivo by FGF13 shRNA, the expression level of
FGF13B was not changed by bevacizumab in vitro. Our study
and our failure to reproduce the perivascular tumor growth
induced by bevacizumab in in vitro models highlight one main
limit of neuro-oncology research, whereby the incomplete
nature of in vitro data may not fit with in vivo results. In the
attempt to overcome this obstacle, we analyzed molecularly the
tumor cells that were selectively retrieved from the brain of rats
treated with bevacizumab, i.e., in the microenvironment where
the tumor cells interact with other cell players of the brain.27 In
general, our results support the concept that bevacizumab elicits
cell features, like spindle-shape and elongated morphology, typ-
ical of invading cells and that tumor spreading occurs along the
perivascular spaces. We also described bevacizumab-related
phenomena, such as tubule generation and niching with endo-
thelial cells, previously reported in GBM stem cells as a result
of their mesenchymal differentiation potentials.5,48,49 In
addition to a deeper morphological dissection of the infiltrative
growth pattern, our methods demonstrate that the perivascular
invasion induced by bevacizumab requires activation of
PLXDC1. The exact function of this trans-membrane receptor
is unknown. In the embryonic brain, PLXDC1 expression over-
laps with the gene PLXDC2, which is more widespread across
the brain and relates with members of the Wnt family that are
involved in axonal guidance.50 PLXDC1 binds to components
of ECM51,52 and is associated with tumor invasion in gastric
cancer.53 PLXDC1 was also been identified in a genome-wide
expression screening of GBM endothelium28 and was proposed
as a possible target for therapeutic anti angiogenic intervention
in cancer.54
In our study, the over-expression of PLXDC1 per se was
able to change partly the growth features of U87MG cells,
whereby they become able to travel for short distances via
vessel cooption. More importantly, inhibition of PLXDC1
expression by shRNA prevented the bevacizumab-induced
infiltrative growth of U87MG cells resulting in a significant
increase of survival. Molecularly, PLXDC1 regulated the EMT
program of tumor cells, whereby its silencing increased the
mRNA levels of epithelial transcripts, whereas those of mesen-
chymal marker genes were reduced.
We also showed that the bevacizumab-induced brain invasion
along perivascular spaces, other than PLXDC1 upregulation by
the tumor cells, required restoration of the endothelial compo-
nent of BBB, which would work as a scaffold for migration. In
support of this finding, bevacizumab is known to restore the BBB
function of U87MG brain xenografts and of human GBM as
well.55,56 To conclude, our work indicates that the brain infiltra-
tion induced by bevacizumab is mainly driven by the vascular
endothelium. We suggest an additional interpretation of the infil-
trative shift of GBM, whereby this antiangiogenic treatment elicits
a vascular-like behavior of the tumor cells that depends on
PLXDC1 activation and that requires the endothelial component
of the BBB as a substrate (Fig. 6).
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